Regenerative medicine is a critical medical field in extending and improving the quality of human life. However, many past and current regenerative medicine treatments such as the use of embryonic stem cells have been met with significant backlash due to ethical and legal concerns. Therefore, IPSCs have the capability of sidestepping these ethical concerns, but require a reformatting of FDA regulations and investment into research targeting the scaling of IPSCs in order for the treatment to reach its full potential.